
    
      The principal objective is to investigate Regorafenib efficacy by prospectively evaluating
      the PFS after the administration of Regorafenib combined with BSC as compared to placebo with
      BSC. Hypothesis is a 50% improvement in median PFS (from 6 weeks to 12 weeks in Regorafenib
      group).
    
  